Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 127,464

Document Document Title
WO/2024/077531A1
The present invention relates to gene segregation and plant improvement, and in particular, to an anti-spotted wilt gene RTSW from tobacco and a use thereof. Provided are a nucleic acid molecule for conferring or enhancing the resistance...  
WO/2024/081858A1
Disclosed are T cell receptors (TCRs) specific for one or more neoantigens and T cells engineered to express said TCRs as well as methods of their use for treating cancer.  
WO/2024/081167A1
The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucl...  
WO/2024/079221A1
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of 5 Bri2 from human (SEQ ID NO: 2); and proteins comprising...  
WO/2024/081746A2
The present invention relates to nucleic acid expression cassettes that are engineered to enhance gene expression. Vectors and methods employing the expression cassettes containing novel chimeric regulatory elements are provided. The inv...  
WO/2024/081604A1
The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for e...  
WO/2024/080824A1
The present invention relates to a novel GLP-1 receptor antagonist analogue and an acylated GLP-1 receptor analogue, and use thereof for preventing or treating congenital hyperinsulinemia or hypoglycemia.  
WO/2024/081372A1
The present invention relates to processes for the preparation of the compound of formula 1 from the intermediates the intermediates of formulae 8 to 10 in the presence of the cyclisation catalyst CuSO4 Compound 1 is the agent-linker con...  
WO/2024/078038A1
Provided in the present invention are a wheat leaf rust resistance protein, and an encoding gene and the use thereof The wheat leaf rust resistant protein comprises any one of the following (a)-(c): (a) a protein, which consists of the a...  
WO/2024/081227A2
The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and/or preventi...  
WO/2024/081768A1
Recombinant bacteria capable of producing and secreting therapeutically active epidermal growth factor (EGF), pharmaceutical compositions thereof, and methods of treating disorders are disclosed.  
WO/2024/079460A1
The present invention relates to novel polypeptide ligands of CXCR1 and/or CXCR2 which are derived from GCP2. The invention also concerns polynucleotides encoding the polypeptide ligands, uses of the polypeptide ligands and compositions ...  
WO/2024/078578A1
The present invention belongs to the technical field of oligosaccharides and glycoconjugates thereof, and specifically relates to a sialic acid (α-(2→6))-D-aminopyran galactose derivative or a salt thereof, a glycoconjugate and a prep...  
WO/2024/080854A1
The present disclosure relates to a fusion molecule is capable of binding to an antigenic substance of which an elevated level or excessive amount causes or results in an immunological disease and inducing phagocytosis, thereby removing,...  
WO/2024/079109A1
The invention relates to a genetically modified natural killer (NK) cell, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular antigen-binding domain that specifically...  
WO/2024/080311A1
[Problem] The present invention addresses the following to-be-solved problems: there are no gene introduction methods that have a high gene introduction efficiency and high specificity for skin, subcutaneous tissues, skin ulcer surfaces,...  
WO/2024/079110A1
The invention relates to a nucleic acid construct for targeting and integrating a binding domain in- frame into an endogenous CD3 epsilon gene of a human cell. The invention further relates to a genetically modified human T cell comprisi...  
WO/2024/079137A1
There is disclosed a mutant, non-naturally occurring or transgenic plant or part of the plant having reduced or inhibited expression or activity of NtNTP2-T or reduced or inhibited expression or activity of NtNTP2-T and NtNTP2-S, said Nt...  
WO/2024/077815A1
Provided are an adeno-associated virus capsid protein mutant having an unactivated T cell targeting property and the use thereof. The mutant comprises a sequence as shown in any one of SEQ ID Nos. 9-12. The recombinant adeno-associated v...  
WO/2024/081940A2
The disclosure provides proteins that can be used as scaffolds to bind a specific target, including specific proteins or peptides of interest, as well as fusion proteins with the scaffolds. Such proteins or peptides of interest may inclu...  
WO/2024/080304A1
One embodiment of the present invention makes it possible to express, in the form of a fusion protein with a serum albumin (SA), a physiologically active protein that is expressed in a low amount and/or is less active when a host cell su...  
WO/2024/078534A1
An interfering RNA for inhibiting MLPH expression, which comprises: any one or more nucleotide sequences as shown in SEQ ID NOs: 1-20 or SEQ ID NOs: 27-38. The siRNA has good activity in inhibiting MLPH mRNA expression, with an inhibitio...  
WO/2024/079358A1
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the...  
WO/2024/079132A1
The invention relates to an adeno-associated virus (AAV) capsid fusion protein comprising comprises an insert comprising a binding domain for a cell surface molecule, in particular, a variable immunoglobulin domain of a heavy chain antib...  
WO/2024/081938A2
The disclosure provides proteins that can be used as scaffolds to bind a specific target, including specific proteins or peptides of interest, as well as fusion proteins with the scaffolds. Such proteins or peptides of interest may inclu...  
WO/2024/081690A2
Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the ...  
WO/2024/081915A1
The present disclosure provides capture proteins for detection of antibodies specific for Kawasaki disease, methods of using the antibodies, and kits comprising the same.  
WO/2024/080682A1
The present invention provides a light chain mutant of botulinum toxin obtained by substituting a specific lysine with arginine in the light chain of botulinum toxin. The light chain mutant of botulinum toxin according to the present inv...  
WO/2024/079249A1
The invention relates to a hybrid AAV vector comprising a transgene of interest operably linked to an hepatocyte-specific promoter, which enhances transgene expression in the liver and its use for liver-directed gene therapy.  
WO/2024/081892A1
Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or...  
WO/2024/079661A1
Provided herein are improved expression constructs for the expression of ATP7B, vectors, and pharmaceutical compositions comprising such constructs. Also provided are methods of treating disease, including, but not limited to, Wilson's D...  
WO/2024/078127A1
The present invention relates to an HIF2α gene mutant, a vector containing the mutant, and the use of the mutant in the construction of a non-alcoholic fatty liver disease (NAFLD) mouse model. The genetically mutated mouse constructed b...  
WO/2024/078597A1
Provided are polypeptides that are engineered RSV prefusion F protein variants, and polynucleotides, vectors, compositions, kits, and methods related to these polypeptides.  
WO/2024/079161A1
The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (En...  
WO/2024/077601A1
A peptide vaccine pharmaceutical composition and a method of use for stimulating immune responses against the glioma H3K27M mutation are provided. Having a length of at least 12 amino acid residues, the peptide vaccine is capable of stim...  
WO/2024/079433A1
The invention relates to heterodimeric pMHC-binding receptors with enhanced discrimination for their target pMHC.  
WO/2024/081544A2
This disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells and/or antigen binding domains targeting CLDN18.2.  
WO/2024/077774A1
Provided is a monoclonal antibody capable of specifically recognizing human CD73 protein and a humanized recombinant antibody thereof, and a reconstructed multifunctional antibody capable of recognizing human CD73 and having an IL15 func...  
WO/2024/080305A1
According to one embodiment of the present invention, a bioactive protein that usually has a low expression level and/or low activity when expressed as a recombinant protein using a host cell such as a CHO cell can be expressed in the fo...  
WO/2024/080637A1
The present invention relates to a virus-like particle combination vaccine comprising influenza A virus antigen protein HA, NA or M2e5x. A recombinant universal influenza-virus-like particle vaccine for protection against infection by in...  
WO/2024/079331A1
The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.  
WO/2024/079043A1
The invention relates to a method of manufacturing a peptide P, which comprises a step of condensing of an alpha amino acid derivative S-am, which has one unprotected alpha amino group or one unprotected alpha imino group, with a protect...  
WO/2024/078124A1
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...  
WO/2024/081933A1
Described herein are methods and compositions for use in generating or promoting an immune response to cancer, comprising administering a combination of an immunotherapy using an immune checkpoint inhibitor, e.g., anti-PD-1 antibodies, a...  
WO/2024/078633A1
Provided is a gene regulation strategy enabling programmable control over eukaryotic translational initiation and use of said gene regulation strategy for various biomedical purposes including but not limited to therapeutic transgene del...  
WO/2024/079292A1
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vect...  
WO/2024/078828A1
The present invention relates to a cell-penetrating polypeptide (CPP), which comprises an amino acid sequence that is derived from, or consists of, a portion of a virulence factor, as well as a complex comprising said CPP, a polynucleoti...  
WO/2024/081625A1
The present invention provides polypeptides, and polypeptide dimers, comprising a modified flavivirus envelope E polypeptide, wherein the modified flavivirus envelope E polypeptide comprises i) a cysteine residue in a fusion loop epitope...  
WO/2024/078479A1
The present invention relates to a heterodimeric fusion protein and the use thereof. The heterodimeric fusion protein of the present invention comprises: a first heavy chain, wherein the first heavy chain comprises a first Fc region and ...  
WO/2024/077376A1
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein....  

Matches 1 - 50 out of 127,464